Gland Pharma surged in trade on the back of positive management commentary. The investors are now focusing on the financials of the company.

The company has seen good growth in the past couple of years. According to the management, margins of 33-35 percent level is sustainable. The cash on the books will be used for M&A and growth.

Ambit has initiated a buy rating on the stock with a target price of Rs 2,109.

For more details, watch video

(Edited by : Bivekananda Biswas)